XML 63 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations - Valuation of Intangible Assets Acquired (Details) - USD ($)
$ in Millions
1 Months Ended
Aug. 31, 2019
Jun. 30, 2019
Oct. 02, 2020
Cancer Treatment Services International      
Business Acquisition [Line Items]      
Tangible assets with finite lives     $ 111.8
In-process R&D with indefinite lives     0.0
Intangible assets     111.8
Cancer Treatment Services International | Technologies      
Business Acquisition [Line Items]      
Tangible assets with finite lives     16.0
Weighted Average Estimated Useful Life (In Years)   7 years  
Cancer Treatment Services International | Customer contracts, supplier relationships, and partner relationships      
Business Acquisition [Line Items]      
Tangible assets with finite lives     50.9
Weighted Average Estimated Useful Life (In Years)   20 years 10 months 24 days  
Cancer Treatment Services International | Trade names      
Business Acquisition [Line Items]      
Tangible assets with finite lives     44.9
Weighted Average Estimated Useful Life (In Years)   17 years 8 months 12 days  
Endocare and Alicon      
Business Acquisition [Line Items]      
Tangible assets with finite lives     64.1
In-process R&D with indefinite lives     12.3
Intangible assets     76.4
Endocare and Alicon | Technologies      
Business Acquisition [Line Items]      
Tangible assets with finite lives     58.8
Weighted Average Estimated Useful Life (In Years)   8 years 1 month 6 days  
Endocare and Alicon | Customer contracts, supplier relationships, and partner relationships      
Business Acquisition [Line Items]      
Tangible assets with finite lives     4.9
Weighted Average Estimated Useful Life (In Years)   8 years  
Endocare and Alicon | Trade names      
Business Acquisition [Line Items]      
Tangible assets with finite lives     0.4
Weighted Average Estimated Useful Life (In Years)   1 year  
Embolics Microspheres Business      
Business Acquisition [Line Items]      
Tangible assets with finite lives     37.8
In-process R&D with indefinite lives     0.0
Intangible assets     37.8
Embolics Microspheres Business | Technologies      
Business Acquisition [Line Items]      
Tangible assets with finite lives     10.6
Weighted Average Estimated Useful Life (In Years) 12 years 6 months    
Embolics Microspheres Business | Customer contracts, supplier relationships, and partner relationships      
Business Acquisition [Line Items]      
Tangible assets with finite lives     20.9
Weighted Average Estimated Useful Life (In Years) 15 years 6 months    
Embolics Microspheres Business | Trade names      
Business Acquisition [Line Items]      
Tangible assets with finite lives     $ 6.3
Weighted Average Estimated Useful Life (In Years) 17 years    
Minimum | Cancer Treatment Services International | Partner Relationships with Hospitals      
Business Acquisition [Line Items]      
Weighted Average Estimated Useful Life (In Years)   22 years  
Maximum | Cancer Treatment Services International | Partner Relationships with Hospitals      
Business Acquisition [Line Items]      
Weighted Average Estimated Useful Life (In Years)   23 years